Additional References
Bleyer AJ, Burke SK, Dillon MA, et al. A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. Am J Kidney Dis. 1999;33(4):694-701.
Burke SK, Slatopolsky EA. Renagel, a novel calcium- and aluminum-free phosphate binder, inhibits phosphate absorption in normal volunteers. Nephrol Dial Transplant. 1997;12(8):1640-44
Chertow GM, Burke SK, Dillon MA, Slatopolsky E. Long-term effects of sevelamer hydrochloride on the calcium x phosphate product and lipid profile of haemodialysis patients. Nephrol Dial Transplant. 1999;14(12):2907-14
Chertow GM, Burke S, Lazarus J, et al. Poly [allylamine hydrochloride]: A noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure. Am J Kidney Dis. 1997;29(1):66-71.
Chertow GM, Martin KJ. Current and future therapies for the medical management of secondary hyperparathyroidism. Semin Dial. 1998;11(5):267-70
Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int. 2002;62:245-52.
Chertow GM, Raggi P, McCarthy JT, et al. The Effects of sevelamer and calcium acetate on proxies of atherosclerotic and arteriosclerotic vascular disease in hemodialysis patients. Am J Nephrol. 2003; 23(5):307-14.
Slatopolsky EA, Burke SK, Dillon MA. Renagel, a non-absorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. Kidney Int. 1999;55(1):299-307
Renagel® (sevelamer hydrochloride) is indicated for the control of serum phosphorus in patients with chronic kidney disease (CKD) on dialysis.
- Renagel is contraindicated in patients with hypophosphatemia or bowel obstruction.
- Caution should be exercised in patients with dysphagia, swallowing disorders, severe gastrointestinal (GI) motility disorders including severe constipation or major GI tract surgery.
- Common adverse events reported with Renagel include vomiting, nausea, diarrhea, dyspepsia, abdominal pain, and constipation.
- Other events reported include pruritus, rash, fecal impaction, and intestinal obstruction.
- Drug-drug interactions may occur with some medications and should be taken into consideration when instructing patients how to take Renagel.
- Patients should be informed to take Renagel with meals and to adhere to their prescribed diets.
Please see accompanying full Prescribing Information.
|  |
Genzyme Corporate
